- Home >
- Clinicals Trials >
- DF6215-001
Back to clinical trials list
DF6215-001
A Phase 1/1b, First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of DF6215 in Patients with Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors
- Open at Paris since : 20/11/2024
- Target : Adult
- Phase : Phase I
Trial description
To determine the maximum tolerated dose (MTD) of DF6215.;To determine clinical activity of DF6215.
Url of the trialMain investigator
